MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting ...
Morning Overview on MSN
New DNA base editor cuts bystander edits while keeping efficiency
Researchers have engineered a new class of adenine base editors that reduce unwanted bystander mutations by two to three ...
The trajectory of base editing has been remarkable, progressing from the laboratory to patient care, treating debilitating or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results